Vaxart - AI Stock Analysis

Analysis generated August 28, 2025

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its proprietary VAAST platform. It aims to revolutionize the approach to immunizations by providing oral vaccines that drive both systemic and mucosal immune responses, potentially offering a higher degree of protection and convenience compared to traditional injectable vaccines.

Fundamental Analysis

For the last quarter, Vaxart reported revenue of $40M. This represents a substantial increase of 90.31% compared to the previous quarter, highlighting positive quarter-over-quarter growth. Even more impressive is the 520.68% increase from the same quarter last year, indicating remarkable year-over-year growth.

Net income for the last quarter was $15M, marking a solid increase of 3.88% quarter-over-quarter and 8.99% year-over-year. This consistent increase is a positive indicator regarding the company's profitability and financial health.

The EBITDA for the last quarter improved to 0 from negative values, registering a 100% increase both quarter-over-quarter and year-over-year. This shift to a neutral EBITDA can be seen as a significant milestone, implying the company is marching towards breakeven or operational efficiency improvements.

Technical Analysis

As of today, Vaxart's stock price stands at $0.36. This indicates a decrease of 12.20% over the last month, which could be a short-term concern for investors. Over the long-term, the stock has experienced a substantial decline of 57.65% from a year ago.

The stock exhibits a neutral trend, with the current SMA10 at $0.36, equal to the previous SMA10. This suggests stability without significant movements. The RSI is at 66.7, indicating a neutral market condition, neither overbought nor oversold.

Alternative Data Analysis

Examining alternative data, Vaxart maintains a stable level of customer engagement, illustrated by an estimated 6,000 visitors to their webpage, with no meaningful change over recent months.

AltIndex provides an AI score of 57 for Vaxart, categorized as a hold signal. This score synthesizes multiple metrics spanning fundamental, technical, and alternative data to forecast Vaxart’s stock price trend.

Conclusion and Recommendation

Considering the comprehensive analysis, Vaxart presents a mixed bag for investors. On the one hand, robust revenue growth, positive net income trends, and a shift to a neutral EBITDA underscore strong financial performance. However, the declining stock price in both short and long terms, along with a neutral technical trend, signals potential caution.

A stable customer engagement level and a hold AI score further indicate that while Vaxart shows promise, it is currently in a hold position. This suggests that potential investors should maintain their current positions while monitoring future developments and await additional positive signals before making sizeable new investments.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.